Does the kinin system mediate in cardiovascular abnormalities? An overview

Area of Science:

• Cardiovascular Physiology
• Molecular Medicine
• Pharmacology

Background:

• The kallikrein-kinin system (KKS) is present in cardiac muscle, and its components are crucial for normal cardiac function.
• Evidence suggests KKS deficiency contributes to cardiovascular diseases like hypertension, ischemia, and myocardial infarction.
• Reduced KKS activity is implicated in conditions such as diabetes, cardiac failure, and left ventricular hypertrophy.

Purpose of the Study:

• To investigate the role of the kallikrein-kinin system in cardiovascular health and disease.
• To explore the therapeutic potential of modulating the KKS for cardiovascular and renal disorders.

Main Methods:

• Review of clinical and experimental data linking KKS activity to cardiovascular pathologies.
• Analysis of the mechanisms underlying the cardioprotective effects of angiotensin-converting enzyme inhibitors.
• Evaluation of kallikrein gene delivery and kinin agonists as therapeutic strategies.

Main Results:

• The KKS is integral to cardiac function, and its deficiency is linked to various cardiovascular diseases.
• Angiotensin-converting enzyme inhibitors exert cardioprotective effects partly through kinin release, aiding in left ventricular hypertrophy regression.
• Kallikrein gene delivery demonstrates broad beneficial effects, suggesting its potential in treating hypertension and cardiovascular/renal diseases.

Conclusions:

• The kallikrein-kinin system is a critical factor in maintaining cardiovascular homeostasis.
• Modulating the KKS, via gene therapy or agonists, offers promising therapeutic avenues for cardiovascular and renal diseases.
• Future development of stable kinin agonists could provide new treatment options for these conditions.